Nano Cap New Millennium Growth Fund L P Acquires New Shares in Harvard Bioscience, Inc. $HBIO

Nano Cap New Millennium Growth Fund L P bought a new position in Harvard Bioscience, Inc. (NASDAQ:HBIO) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 600,000 shares of the medical instruments supplier’s stock, valued at approximately $401,000. Nano Cap New Millennium Growth Fund L P owned approximately 1.34% of Harvard Bioscience at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Bank of America Corp DE grew its position in shares of Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after purchasing an additional 11,948 shares in the last quarter. Gamco Investors INC. ET AL purchased a new position in shares of Harvard Bioscience during the 4th quarter valued at $38,000. Jane Street Group LLC grew its position in shares of Harvard Bioscience by 491.9% during the 2nd quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 58,785 shares in the last quarter. Williams & Novak LLC increased its stake in Harvard Bioscience by 26.6% in the 4th quarter. Williams & Novak LLC now owns 348,800 shares of the medical instruments supplier’s stock worth $233,000 after acquiring an additional 73,300 shares during the last quarter. Finally, Acadian Asset Management LLC increased its stake in Harvard Bioscience by 7.8% in the 1st quarter. Acadian Asset Management LLC now owns 1,077,069 shares of the medical instruments supplier’s stock worth $606,000 after acquiring an additional 78,276 shares during the last quarter. 80.87% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Harvard Bioscience news, Director William Snider acquired 8,475 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was acquired at an average price of $4.85 per share, for a total transaction of $41,103.75. Following the acquisition, the director owned 32,000 shares in the company, valued at $155,200. This represents a 36.03% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Stephen J. Denelsky acquired 10,000 shares of the company’s stock in a transaction on Tuesday, March 17th. The stock was acquired at an average price of $4.87 per share, with a total value of $48,700.00. Following the acquisition, the director owned 21,000 shares in the company, valued at approximately $102,270. This trade represents a 90.91% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders acquired 36,000 shares of company stock worth $177,354. 20.30% of the stock is currently owned by company insiders.

Harvard Bioscience Trading Up 2.2%

NASDAQ:HBIO opened at $5.52 on Friday. The company has a fifty day moving average of $5.62 and a 200 day moving average of $6.05. Harvard Bioscience, Inc. has a 52 week low of $2.81 and a 52 week high of $9.50. The company has a quick ratio of 1.06, a current ratio of 1.99 and a debt-to-equity ratio of 3.60. The firm has a market capitalization of $24.90 million, a P/E ratio of -2.54 and a beta of 1.57.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Tuesday, May 12th. The medical instruments supplier reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.29. Harvard Bioscience had a negative net margin of 11.44% and a negative return on equity of 25.78%. The company had revenue of $20.76 million during the quarter, compared to analyst estimates of $21.20 million.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Wall Street Zen cut shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Friday, March 27th. Benchmark lowered their price objective on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a research report on Friday, March 13th. Finally, New Street Research set a $6.00 price objective on shares of Harvard Bioscience in a research report on Friday, March 13th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Harvard Bioscience has a consensus rating of “Hold” and an average price target of $6.00.

Harvard Bioscience Profile

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.